At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, biotechnology giant Moderna signaled a profound strategic expansion beyond its highly successful infectious disease…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…
Read More
Immunai and Boehringer Ingelheim Forge Strategic Alliance to Uncover Novel T-Cell Targets in Oncology and Autoimmune Diseases
Immunai, a leading artificial intelligence (AI) company specializing in immune system analysis, and Boehringer Ingelheim, a global biopharmaceutical giant, have…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read MoreYOU MAY HAVE MISSED
